FDA’s oncology adcomm to review GSK’s Blenrep relaunch plans

The FDA’s Oncologic Drugs Advisory Committee will meet on July 17 to discuss a potential relaunch of GSK’s multiple myeloma drug Blenrep. The committee will consider GSK’s application to bring Blenrep …